Shi S, Yu X J
Department of Pancreatic Surgery,Fudan University Shanghai Cancer Center; Department of Oncology,Shanghai Medical College,Fudan University,Shanghai 200032,China.
Zhonghua Wai Ke Za Zhi. 2021 Jul 1;59(7):593-596. doi: 10.3760/cma.j.cn112139-20210406-00161.
The prognosis of pancreatic cancer patients with liver metastasis (PCLM) is very poor and the median overall survival(OS) is less than 6 months.The current standard treatment for PCLM is systematic chemotherapy.Though the chemotherapeutic regimens are better than gemcitabine only,the OS remains dissatisfied.A lot of retrospective studies identified that surgical treatment can only offer survival benefits for highly selected rather than entire PCLM patients.The Chinese Study Group for Pancreatic Cancer (CSPAC) has initiated a multiple-center,prospective,randomized comparison clinical trial,named CSPAC-1 to identify the standard and value of surgical treatment of PCLM patients.This manuscript reviewed the current progress of surgical treatment for pancreatic cancer with liver metastasis and looked forward to opportunities and challenges in the future.
伴有肝转移的胰腺癌（PCLM）患者预后很差，中位总生存期（OS）不足6个月。PCLM目前的标准治疗是全身化疗。尽管化疗方案比单纯吉西他滨有所改善，但OS仍不尽人意。许多回顾性研究表明，手术治疗仅能为经过严格筛选的PCLM患者而非所有患者带来生存获益。中国胰腺癌研究组（CSPAC）启动了一项多中心、前瞻性、随机对照临床试验，即CSPAC-1，以明确PCLM患者手术治疗的标准及价值。本文回顾了伴有肝转移的胰腺癌手术治疗的当前进展，并展望了未来的机遇与挑战。
